Therapeutic Indications

Alectinib is indicated for:

Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Irrespective of gender only Adults (18 years old or older)

Alectinib as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Alectinib as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 1200 mg in 2 divided doses daily